Stories > FDA Investigates CAR T Therapies

FDA Investigates CAR T Therapies

4D Molecular Therapeutics Raises $300 Mi...

AB-2100 Phase 1/2 Trial Initiated

AGO Recognition Boosts BluePrint® Impact

Affini-T Therapeutics at J.P. Morgan Hea...

Allogene Therapeutics Restates Financial...

Cue Biopharma to Present Corporate Updat...